Tag: biotechnology
-
Electric Pulses Induce Lung Cancer Immune Response
Results of a clinical trial show a lung cancer therapy using highly focused pulses with electrical energy show signs of immune responses that can treat the patients’ tumors.
-
Merger to Form Programmable Nano-Medicines Company
A life science venture investor is merging two of its biotechnology portfolio companies to form a single developer of nanoscale medications with programmable properties.
-
Organ Chip Devices to Model for Radiation Sickness
The U.S. government’s health preparedness agency awarded a contract with a university lab to explore organ models on chips to document effects of radiation sickness.
-
Start-Up Adapts Crispr for Molecular Detection, Raises $40M
A new company is underway that says it adapts the gene editing technique Crispr to make detecting nucleic acid targets like DNA or RNA faster and simpler.
-
High-Speed Biologic Injection Device Shown Feasible
A developer of an auto-injection technology says its device can deliver a biologic drug under the skin in a fraction of the time of conventional syringes.
-
Infographic – Q3 Life Science Venture Funds Tick Up
Venture investments in U.S. life science and biotechnology start-ups in the third quarter of 2023 rose from the previous two quarters to reach pre-pandemic levels.
-
Longevity Science Group Spins-Off Biotech Start-Up
An organization funding research on extending the human life span by preventing age-related diseases is founding its first biotechnology company.
-
Collapsed Microbiome Biotech Sells Off Assets
A developer of therapies addressing the body’s microbe communities is selling off key assets to another biotechnology company, after problems developed with its lead program.
-
Neuro Disease Biotech Gains $61M in Early Funds
A developer of treatments for Alzheimer’s disease that seeks to improve the condition of the brain’s support cells is raising £48 million ($US 61 million) in its first venture round.
-
NIH Funds Antibody Discovery for Difficult Protein Targets
A biotechnology company is receiving NIH support for discovering antibodies that address the vast majority of proteins coded by the human genome, passed-up so far by drug makers.